News Search
|
All News Topics
>
Frankfurt Stock Exchange
;
Press Releases by Industry Channel
>
All Frankfurt Stock Exchange Press Releases
Scientific Committee of Largest-Ever Multinational European Dialysis Research Initiative Announced
BARCELONA, Spain--Amgen (Europe) GmbH and Fresenius Medical Care Europe today announced formation of the Scientific Committee of the largest-ever multinational European dialysis research initiative, designed to study European dialysis practice patterns to optimise care and improve survival of chronic kidney disease (CKD) patients on dialysis. The Scientific Steering Committee will be led by Professor Jrgen Floege, Head of Nephrology and Immunology, Medizinische Klinik II, RWTH Aachen, Germany, and co-chaired by Professor Kai-Uwe Eckardt, Head of the Nephrology/Hypertension Section, University of Erlangen-Nuremberg, Germany. The committee members include ten internationally-renowned scientists with expertise in nephrology, cardiology and epidemiology.
"The burden and prevalence of European dialysis patients are substantial, requiring a more urgent need to address concerns that have not been studied through a large European patient database," said Professor Floege. "This initiative, which offers unparalleled access to the largest database of European dialysis patients, promises to find answers to clinically important questions. Through the conduct, clinical expertise and leadership of this initiative, we hope to improve the survival of thousands of dialysis patients across Europe."
The Committee's research will be based on a retrospective open-cohort study of anonymised Fresenius Medical Care Europe data from over 11,000 patients, representing more than 15,000 patient-years of data. The open-cohort study involves patients from 11 countries, including France, United Kingdom, Italy, Spain, Portugal, Hungary, Turkey and Central Eastern European countries (Poland, Czech Republic, Slovakia and Slovenia). The Committee will identify research questions, support appropriate analyses, and communicate results with the nephrology community via scientific journals and presentations at medical congresses throughout the coming years.
About Amgen and Fresenius Medical Care Europe Research Initiative
On 1 February, 2007, Amgen (Europe) GmbH and Fresenius Medical Care Europe announced a European research initiative that will help optimise care for patients with chronic kidney disease (CKD). The multi-year initiative seeks to improve the quality of medical care for patients suffering from CKD and associated illnesses, through data analyses, education and research. A Scientific Committee Group of Experts will serve as advisors to Amgen for the conduct of these research studies.
The Committee includes the following members:
* Chairman - Professor Jrgen Floege, Head of Nephrology and Immunology, Medizinische Klinik II, RWTH Aachen, Germany
* Co-Chairman - Professor Kai-Uwe Eckardt, Head of Nephrology and Hypertension, University of Erlangen-Nuremberg, Germany
* Professor Pedro Aljama: Head of Renal Unit, University Hospital Reina Sofia, Crdoba, Spain
* Professor Stefan Anker: Professor of Cachexia, Charit Campus Virchow-Klinikum, Berlin, Germany
* Professor Bernard Canaud: Head of Nephrology, Lapeyronie University Hospital, Montpellier, France
* Professor Tilman Dreke: Associate Professor, Department of Nephrology, Necker Hospital, Paris, France
* Professor ALM de Francisco: Head of Dialysis Unit, Department of Nephrology, Valdecilla University Hospital, Santander, Spain
* Dr Iain MacDougall: Consultant Nephrologist and Honorary Senior Lecturer, Kings College Hospital, London, UK
* Professor Peter Stenvinkel: Associate Professor and Senior Lecturer, Karolinska University Hospital, Huddinge, Sweden
* Dr David Wheeler: Reader in Nephrology, Royal Free and University College Medical School, London, UK
About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products, services and therapies for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS-p). For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.
Amgen Forward-Looking Statement
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2005 and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, sales growth of recently launched products, difficulties or delays in manufacturing our products and regulatory developments (domestic or foreign) involving current and future products and manufacturing facilities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify side effects or manufacturing problems with our products after they are on the market. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. Further, some raw materials, medical devices and component parts for our products are supplied by sole third party suppliers.
Contacts
Amgen
Marie Fay, +41 41 3690 339 (media)
Arvind Sood, +1 805-447-1060 (investors)
or
Fresenius Medical Care Europe
Dr Bernd Ebeling, Corporate Communications (media)
+ 49 6172 6082378
pr@fmc-ag.de
"The burden and prevalence of European dialysis patients are substantial, requiring a more urgent need to address concerns that have not been studied through a large European patient database," said Professor Floege. "This initiative, which offers unparalleled access to the largest database of European dialysis patients, promises to find answers to clinically important questions. Through the conduct, clinical expertise and leadership of this initiative, we hope to improve the survival of thousands of dialysis patients across Europe."
The Committee's research will be based on a retrospective open-cohort study of anonymised Fresenius Medical Care Europe data from over 11,000 patients, representing more than 15,000 patient-years of data. The open-cohort study involves patients from 11 countries, including France, United Kingdom, Italy, Spain, Portugal, Hungary, Turkey and Central Eastern European countries (Poland, Czech Republic, Slovakia and Slovenia). The Committee will identify research questions, support appropriate analyses, and communicate results with the nephrology community via scientific journals and presentations at medical congresses throughout the coming years.
About Amgen and Fresenius Medical Care Europe Research Initiative
On 1 February, 2007, Amgen (Europe) GmbH and Fresenius Medical Care Europe announced a European research initiative that will help optimise care for patients with chronic kidney disease (CKD). The multi-year initiative seeks to improve the quality of medical care for patients suffering from CKD and associated illnesses, through data analyses, education and research. A Scientific Committee Group of Experts will serve as advisors to Amgen for the conduct of these research studies.
The Committee includes the following members:
* Chairman - Professor Jrgen Floege, Head of Nephrology and Immunology, Medizinische Klinik II, RWTH Aachen, Germany
* Co-Chairman - Professor Kai-Uwe Eckardt, Head of Nephrology and Hypertension, University of Erlangen-Nuremberg, Germany
* Professor Pedro Aljama: Head of Renal Unit, University Hospital Reina Sofia, Crdoba, Spain
* Professor Stefan Anker: Professor of Cachexia, Charit Campus Virchow-Klinikum, Berlin, Germany
* Professor Bernard Canaud: Head of Nephrology, Lapeyronie University Hospital, Montpellier, France
* Professor Tilman Dreke: Associate Professor, Department of Nephrology, Necker Hospital, Paris, France
* Professor ALM de Francisco: Head of Dialysis Unit, Department of Nephrology, Valdecilla University Hospital, Santander, Spain
* Dr Iain MacDougall: Consultant Nephrologist and Honorary Senior Lecturer, Kings College Hospital, London, UK
* Professor Peter Stenvinkel: Associate Professor and Senior Lecturer, Karolinska University Hospital, Huddinge, Sweden
* Dr David Wheeler: Reader in Nephrology, Royal Free and University College Medical School, London, UK
About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of products, services and therapies for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,194 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 169,216 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS-p). For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.
Amgen Forward-Looking Statement
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2005 and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, sales growth of recently launched products, difficulties or delays in manufacturing our products and regulatory developments (domestic or foreign) involving current and future products and manufacturing facilities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify side effects or manufacturing problems with our products after they are on the market. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. Further, some raw materials, medical devices and component parts for our products are supplied by sole third party suppliers.
Contacts
Amgen
Marie Fay, +41 41 3690 339 (media)
Arvind Sood, +1 805-447-1060 (investors)
or
Fresenius Medical Care Europe
Dr Bernd Ebeling, Corporate Communications (media)
+ 49 6172 6082378
pr@fmc-ag.de
Powered by
Distribution channels:
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
